Cargando…

Structure-based drug discovery of a corticotropin-releasing hormone receptor 1 antagonist using an X-ray free-electron laser

Thus far, attempts to develop drugs that target corticotropin-releasing hormone receptor 1 (CRF(1)R), a drug target in stress-related therapy, have been unsuccessful. Studies have focused on using high-resolution G protein-coupled receptor (GPCR) structures to develop drugs. X-ray free-electron lase...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hoyoung, Lim, Taehyun, Ha, Go Eun, Lee, Jee-Young, Kim, Jun-Woo, Chang, Nienping, Kim, Si Hyun, Kim, Ki Hun, Lee, Jaeick, Cho, Yongju, Kim, Byeong Wook, Abrahamsson, Alva, Kim, Sung Hwan, Kim, Hyo-Ji, Park, Sehan, Lee, Sang Jae, Park, Jaehyun, Cheong, Eunji, Kim, B. Moon, Cho, Hyun-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545732/
https://www.ncbi.nlm.nih.gov/pubmed/37653040
http://dx.doi.org/10.1038/s12276-023-01082-1
Descripción
Sumario:Thus far, attempts to develop drugs that target corticotropin-releasing hormone receptor 1 (CRF(1)R), a drug target in stress-related therapy, have been unsuccessful. Studies have focused on using high-resolution G protein-coupled receptor (GPCR) structures to develop drugs. X-ray free-electron lasers (XFELs), which prevent radiation damage and provide access to high-resolution compositions, have helped accelerate GPCR structural studies. We elucidated the crystal structure of CRF(1)R complexed with a BMK-I-152 antagonist at 2.75 Å using fixed-target serial femtosecond crystallography. The results revealed that two unique hydrogen bonds are present in the hydrogen bond network, the stalk region forms an alpha helix and the hydrophobic network contains an antagonist binding site. We then developed two antagonists—BMK-C203 and BMK-C205—and determined the CRF(1)R/BMK-C203 and CRF(1)R/BMK-C205 complex structures at 2.6 and 2.2 Å, respectively. BMK-C205 exerted significant antidepressant effects in mice and, thus, may be utilized to effectively identify structure-based drugs against CRF(1)R.